LivaNova PLC (NASDAQ:LIVN) Given Average Rating of “Moderate Buy” by Brokerages

LivaNova PLC (NASDAQ:LIVN) has been given a consensus recommendation of “Moderate Buy” by the ten research firms that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $74.7778.

LIVN has been the subject of several research reports. Piper Sandler restated an “overweight” rating and set a $85.00 price objective on shares of LivaNova in a research report on Thursday, February 19th. Weiss Ratings reiterated a “sell (d+)” rating on shares of LivaNova in a report on Monday, December 29th. Wall Street Zen raised LivaNova from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 20th. Stifel Nicolaus set a $80.00 price objective on LivaNova in a research report on Wednesday, February 25th. Finally, Barclays increased their price objective on LivaNova from $67.00 to $73.00 and gave the company an “equal weight” rating in a research note on Friday, February 27th.

LivaNova Price Performance

Shares of NASDAQ LIVN opened at $61.85 on Monday. The stock has a market cap of $3.38 billion, a price-to-earnings ratio of -13.87 and a beta of 0.92. LivaNova has a 52 week low of $32.48 and a 52 week high of $71.92. The company’s 50-day moving average price is $64.91 and its 200 day moving average price is $60.14. The company has a current ratio of 1.36, a quick ratio of 1.16 and a debt-to-equity ratio of 0.29.

LivaNova (NASDAQ:LIVN) last announced its earnings results on Wednesday, February 25th. The company reported $0.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.80 by $0.06. LivaNova had a negative net margin of 17.46% and a positive return on equity of 16.54%. The company had revenue of $360.92 million during the quarter, compared to analysts’ expectations of $354.31 million. During the same quarter in the previous year, the business posted $0.81 earnings per share. The firm’s quarterly revenue was up 12.2% compared to the same quarter last year. LivaNova has set its FY 2026 guidance at 4.150-4.250 EPS. As a group, research analysts forecast that LivaNova will post 2.85 earnings per share for the current fiscal year.

Institutional Investors Weigh In On LivaNova

Several hedge funds have recently modified their holdings of LIVN. Hantz Financial Services Inc. grew its holdings in shares of LivaNova by 159.9% during the fourth quarter. Hantz Financial Services Inc. now owns 434 shares of the company’s stock worth $27,000 after buying an additional 267 shares in the last quarter. State of Wyoming purchased a new position in shares of LivaNova during the second quarter valued at approximately $31,000. EverSource Wealth Advisors LLC boosted its position in LivaNova by 998.4% during the second quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock worth $32,000 after acquiring an additional 639 shares during the last quarter. Quarry LP acquired a new stake in LivaNova during the third quarter worth approximately $36,000. Finally, UMB Bank n.a. grew its stake in LivaNova by 63.0% in the 3rd quarter. UMB Bank n.a. now owns 792 shares of the company’s stock worth $41,000 after acquiring an additional 306 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.